BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kosugi S, Imai Y, Kurata Y, Tomiyama Y, Shiraga M, Honda S, Nishikawa M, Yonezawa T, Kanakura Y, Matsuzawa Y. Platelet-associated IgM elevated in patients with chronic hepatitis C contains no anti-platelet autoantibodies. Liver. 1997;17:230-237. [PMID: 9387914 DOI: 10.1111/j.1600-0676.1997.tb01023.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Sekiguchi T, Nagamine T, Takagi H, Mori M. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol 2006;12:1205-10. [PMID: 16534872 DOI: 10.3748/wjg.v12.i8.1205] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Dormann H, Krebs S, Muth-Selbach U, Brune K, Schuppan D, Hahn EG, Schneider HT. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C. J Hepatol. 2000;32:1041-1042. [PMID: 10898329 DOI: 10.1016/s0168-8278(00)80113-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Panzer S, Seel E, Brunner M, Körmöczi GF, Schmid M, Ferenci P, Peck-Radosavljevic M. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol. 2006;77:513-517. [PMID: 17042765 DOI: 10.1111/j.0902-4441.2006.t01-1-ejh2888.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
4 Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75:417-423. [PMID: 16191092 DOI: 10.1111/j.1600-0609.2005.00524.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
5 Karakan T, Cindoruk M, Degertekin B, Dogan I, Sancak A, Dumlu S, Gorgul A, Unal S. Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia. Curr Ther Res Clin Exp 2005;66:247-53. [PMID: 24764593 DOI: 10.1016/j.curtheres.2005.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68:202-209. [PMID: 11754404 DOI: 10.1002/ajh.1180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
7 García-Suárez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol. 2000;110:98-103. [PMID: 10930984 DOI: 10.1046/j.1365-2141.2000.02132.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
8 Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, Kashiwagi S. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000;45:2221-8. [PMID: 11215743 DOI: 10.1023/a:1026696721059] [Cited by in Crossref: 38] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
9 Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818-824. [PMID: 15953010 DOI: 10.1111/j.1365-2141.2005.05542.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]